Ken Griffin Xeris Biopharma Holdings, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 437,612 shares of XERS stock, worth $3.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
437,612
Previous 18,100
2317.75%
Holding current value
$3.17 Million
Previous $84,000
4119.05%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding XERS
# of Institutions
236Shares Held
94.1MCall Options Held
251KPut Options Held
61.8K-
Black Rock Inc. New York, NY10.3MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.83MShares$71.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.84MShares$42.3 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.14MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $986M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...